Medigene will make its clinical debut in TCR, in a collaboration with the Max Delbrück Centre and the Charité Hospital in Berlin. The planned Phase I trial focus on the blood cancer multiple myeloma.
Based near Munich (Germany), Medigene develops different anti-cancer cell therapies, as we recently discussed in an interview with former CFO Peter Llewellyn-Davies. It is actually one of the key European players in the TCR field (a kind of ‘younger sibling’ of CAR-T), along with Immunocore and Adaptimmune.
In fact, Medigene used to hold shares in Immunocore until recently. In April, it sold 50% of its stake in this true money-magnet for €6.1M to focus on its own TCR program.
Now, a TCR that has been developed during a special research program called SFB 36 involving the workgroups of Prof. Thomas Blankenstein from the Max Dellbrück Center and Prof Dolores Schendel from Medigene will take an important step forward. It will be used in a Phase I trial for patients with relapsed/refractory multiple myeloma (a type of blood cancer).